Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Cell, Regenerative Therapy Environment ‘Exciting’ But Ongoing Dialog Needed

Executive Summary

While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.

Advertisement

Related Content

PMDA Chief Defends Japan Spinal Cord Therapy Approval
Japan Firms Up Cost-Effectiveness Plans As Industry Concerns Linger
J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
‘Drastic’ Japan Price Reforms Hitting R&D Incentives, Plans - EFPIA
Japan’s Healios Eyes First Approvals As It Progresses Regenerative Therapies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125017

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel